By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > News > Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
News

Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery

Last updated: 18/07/2025 12:36 PM
Published: 18/07/2025
Share
SHARE

MILAN, July 17, 2025 /PRNewswire/ — A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing an anti-inflammatory steroid and a quinolone antibiotic, developed by NTC, indicated for the prevention and treatment of inflammation and prevention of infection following cataract surgery in adults. The study was submitted when nearly 4 million patients across about 60 countries worldwide were treated with this drug.

- Advertisement -

Conducted by Italian researchers and supported by NTC, the study analyzed public safety data registered in the adrreports.eu portal, that collects safety reports from EudraVigilance, the European Medicines Agency’s official adverse drug reaction (ADR) database. The study identified only 53 ADRs occurred in 25 patients between 2020 and 2024. Key findings include:

- Advertisement -
  • 74% of ADRs were non-serious.
  • More than half were deemed unlikely to be related to the product.
  • The most frequently reported events were mild reactions involving the eye or skin—expected outcomes for a topically administered ophthalmic solution.
  • No case of endophthalmitis, a severe and rare infection that can occur following eye surgery, was reported.

“This is the first international pharmacovigilance study focused specifically on a fixed-dose eye drop combining an antibiotic and an anti-inflammatory steroid,” said Dr. Giorgio Ciprandi, senior author of the publication. “Its wide usage and favorable safety profile make of it a valuable option in the modern management of post-cataract patients’.”

- Advertisement -

The findings support the current recommendation of a short-term, seven-day treatment course, which improves patient adherence and limits the risk of side effects or antibiotic resistance.

- Advertisement -

The study also highlights the importance of pharmacovigilance in evaluating medicines after market approval. “This analysis confirms how continuous safety monitoring is essential to protect patients and support clinicians based on safety information collected from the spontaneous reporting,” said Alessandro Colombo, CSO in NTC.

- Advertisement -

Cataract surgery remains the most common ophthalmic procedure worldwide, and post-operative management is critical to ensure optimal recovery. Since its approval in 2020, this innovative combination has provided patients with a simplified one-week treatment regimen that reduces unnecessary exposure to antibiotics and minimizes the risks associated with prolonged steroid use.

- Advertisement -

Thanks to its consistent safety profile, the product has received marketing authorization renewal from European regulatory authorities.

- Advertisement -

About the Study
The study, titled “Pharmacovigilance on dexamethasone 1mg/mL + levofloxacin 5 mg/mL eye drops, solution: a five-year registry.”, was conducted by experts in ophthalmology and drug safety.

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/five-year-pharmacovigilance-study-by-ntc-confirms-safety-of-fixed-dose-eye-drops-for-post-cataract-surgery-302505372.html

- Advertisement -
NYSE Content Advisory: Pre-Market update + FIFA World Cup 2026 NY/NJ Host Committee to ring the opening bell
Natural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+ Company
Amity Innovation Incubator’s Investor Pitch Day Showcases India’s Next Generation of Disruptive Startups
Nura Wallet Drops Major Update: Native Staking, AI Integrations & On-Chain Rewards Go Live
KPM Analytics Expands Vision Inspection Manufacturing Facilities to Support Baking and Snack Food Brands
TAGGED:confirmsdropseyefive-yearfixed-dosefornewsntcpharmacovigilancepost-cataractsafetystudysurgery:
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Olympism365 Summit: IOC President calls on global participants to join forces to use sport to serve society
Esports

Olympism365 Summit: IOC President calls on global participants to join forces to use sport to serve society

TheNews Market
TheNews Market
04/06/2025
STAR OF THE SEAS OFFICIALLY JOINS ROYAL CARIBBEAN AS THE NEXT ICONIC VACATION
MAIDO, LIMA, IS NAMED NO.1 IN THE LIST OF THE WORLD’S 50 BEST RESTAURANTS 2025
Lucinity Launches AI-Native Customer 360, Powered by Agentic AI
WISeKeys Subsidiaries WISeSat and SEALSQ Launch New Satellite with SpaceX, Enabling the First-Ever DePIN from Space and Advancing Quantum-Safe Space Communications
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?